Skip to main content
. Author manuscript; available in PMC: 2016 Jan 21.
Published in final edited form as: Expert Opin Investig Drugs. 2013 Nov 20;23(2):243–254. doi: 10.1517/13543784.2014.852536

Figure 3. GLYX-13 has antidepressant-like properties without psychotomimetic side effects in rats.

Figure 3

(A – D) The antidepressant-like effects of an optimal antidepressant-like dose of GLYX-13 (3 mg/kg IV) in the rat Porsolt test measured at 1 h (A) or 24 h (B) post-dosing G, the novelty-induced hypophagia test 1 h post-dosing (C) or the learned helplessness test 24 h post dosing (D). GLYX-13 does not show ketamine-like discriminative stimulus effects (E) or sedative effects (F) in rats trained to discriminate 10 mg/kg ketamine from saline. (G – H) GLYX-13 (10 mg/kg IV) does not show ketamine-like rewarding effects in the conditioned place preference (G) or sensory-motor gating deficits in the pre-pulse inhibition (H) tests in rats.

Data are expressed as Mean ± SEM. *p < 0.05 Fisher’s PLSD post hoc test vs. vehicle.

Data adapted from [34] with permission of Nature Publishing Group.